WASHINGTON — The Trump administration’s agreement with Eli Lilly and Novo Nordisk regarding GLP-1 obesity drugs was predicated on the expectation of reduced prices in return for increased sales volume. However, reports indicate that these companies have managed to achieve higher sales without necessarily adhering to the promised lower prices.
In November, negotiators for President Trump secured a monthly price of $245 for GLP-1 medications under Medicare and Medicaid, intended to apply to all such drugs, including those for obesity, which previously lacked Medicare coverage. This pricing structure, however, was contingent upon private Medicare insurers agreeing to cover the drugs across all indications, with a stipulated $50 copay—a condition not disclosed publicly by the administration.
As confirmed by Novo and Lilly, this undisclosed stipulation raises questions about the transparency and effectiveness of the negotiation process. For B2B professionals in the pharmaceutical sector, this development underscores the complexities of pricing agreements and the potential implications for market access and reimbursement strategies.
Get started today with Solo access →
